PharmiNews

The Directory of Pharma Companies and News

Takeda

Category: Pharmaco
Category: Pharmaco

Takeda News

DateNews
2017-02-28Bushu and Takeda Announce Transformational Pharmaceutical Sciences Partnership
2017-02-22Takeda's CSR Data Book 2016 Receives Good Performance Prize in the Environmental Report Section of the 20th Environmenta...
2017-02-20Takeda Announces Further Details of Splitting off (Simple Absorption-type Split) of Japan Consumer Healthcare Business U...
2017-02-17Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation ...
2017-02-17Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn...
2017-02-16Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
2017-02-15PRA Health Sciences and Takeda Partnership Expands to Japan
2017-02-08Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology ...
2017-02-01Takeda reports Q3 FY2016 results and improves year-end outlook
2017-01-31EXELIXIS AND TAKEDA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE AND DEVELOP NOVEL CANCER THERAPY CABOZANTI...
2017-01-20Takeda Recognized as one of the Global 100 Most Sustainable Corporations for second consecutive year
2017-01-20Takeda Commences Cash Tender Offer for all Outstanding Shares of ARIAD Pharmaceuticals, Inc.
2017-01-18Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in...
2017-01-11Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies
2017-01-09Takeda to Acquire ARIAD Pharmaceuticals, Inc.
2017-01-06Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease
2016-12-15Takeda Announces Sale of Shareholding in Wako Pure Chemical Industries, Ltd. to Fujifilm Corporation
2016-12-12GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor...
2016-12-04Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for C...
2016-12-02CEREVANCE LAUNCHED WITH NEW TECHNOLOGY, DRUG PORTFOLIO AND $36M IN CASH TO TACKLE BRAIN DISEASES
2016-11-30Takeda to invest more than 100 Million Euros in Dengue Vaccine Manufacturing plant in Germany
2016-11-29Inisync® Combination Tablets Now Available for the Treatment of Type 2 Diabetes in Japan
2016-11-24NINLAROTM ?ixazomib? Receives Conditional Approval from the European Commission to Treat Multiple Myeloma
2016-11-11Takeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus
2016-09-28Takeda Obtains New Drug Application Approval for Inisync® Combination Tablets for the Treatment of Type 2 Diabetes in Ja...
2016-09-21Takeda and Affilogic enter into Research Collaboration to Develop Nanofitin®-based Therapies in Central Nervous System
2016-09-21Takeda has been selected for the seventh consecutive year for Dow Jones Sustainability Asia Pacific Index
2016-09-21Takeda and Zydus Cadila partner to address the global threat of Chikungunya
2016-09-16Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patient...
2016-09-16Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLARO (ixazomib), the First Oral Proteasome Inhibito...
2016-09-12Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership
2016-09-12Takeda Supports Global Expansion of the American Cancer Society's Relay For Life (RFL)
2016-09-12Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement
2016-09-09Japan International Cooperation Agency (JICA) Supports Takeda's Access to Medicines Strategy in a Public-Private-Partner...
2016-09-07Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)
2016-09-02Takeda to develop Zika Vaccine with up to $312 million in funding from US Government
2016-08-31Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma
2016-08-26Takeda Announces Bold, New Access to Medicines Strategy
2016-08-08Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma
2016-08-05Termination of Cooperative Commercialization of PREVENAR13® and BENEFIX® in Japan
2016-08-02Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx...
2016-08-01Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin...
2016-07-29Takeda Refocuses Research & Development On Targeted Therapeutic Areas, Concentrating in Japan and the U.S.
2016-07-29Takeda Reports 1st Quarter 2016 Resultswith a Strong Start to the Year and Confidence in Management Guidance
2016-07-18Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal ...
2016-07-13IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Di...
2016-07-06Takeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Tran...
2016-07-05Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fist...
2016-07-04Takeda to Partner with Altos Therapeutics to Develop Promising Compound for the Treatment of Gastroparesis
2016-07-04Takeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan
2016-06-24Takeda Revises Collaboration Agreement with Amgen, Returning the Development and Commercialization Rights of Molecules /...
2016-06-22TB Alliance and Takeda announce advancement of joint program investigating promising compounds for novel TB therapies th...
2016-06-20Takeda Initiates World's First Norovirus Vaccine Field Trial
2016-06-17Takeda Announces Support to Japan Voluntary Organizations Active in Disaster (JVOAD)
2016-06-17Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.
2016-06-16Civil Society Initiative Subsidy Program Takeda Well-Being Program II : Giving Children in Long-term Treatment the Energ...
2016-06-16Takeda and M2Gen Collaborate with ORIEN to Speed Clinical Development and Discovery of Cancer Treatments Through Health ...
2016-06-12EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Di...
2016-06-08Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases
2016-06-08Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointe...
2016-06-07VONOSAP® pack 400, VONOSAP® pack 800 and VONOPION® pack (triple-drug blister packs containing TAKECAB® tablet) Now Avail...
2016-06-07Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate C...
2016-06-06Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions
2016-06-02Trintellix (vortioxetine) Now Available in U.S. Pharmacies
2016-05-27Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation Treatment in Post-Transplant ...
2016-05-27Takeda Provides Update on EU Marketing Authorization Application for NINLARO® (ixazomib) in Relapsed/Refractory Multiple...
2016-05-24Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting
2016-05-23Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adult...
2016-05-16Adoption of New Long-Term Incentive Plan for Members of the Board of Directors
2016-05-16Continuation of Stock Grant System (Global Long-Term Incentive Plan) for Company Group Management in Japan and Overseas ...
2016-05-12Takeda Appoints New Chief Financial Officer, James Kehoe
2016-05-10Takeda Reports Results for Fiscal Year 2015 (April 2015 -March 2016) and Forecast for Fiscal Year 2016
2016-05-10Takeda Announces Candidates for New Directors after the Transition to a Company with Audit and Supervisory
2016-05-09Takeda Receives $38 Million Grant from the Bill & Melinda Gates Foundation to Support Polio Eradication in Developing Co...
2016-05-03Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
2016-04-28Takeda Announces its Transition to a Company with Audit and Supervisory Committee and Partial Amendment to the Articles ...
2016-04-28Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Med...
2016-04-27European Commission Approves Surgical Patch TachoSil® (human thrombin/human fibrogen) for Use in Neurological Surgery
2016-04-01Takeda and Teva Establish "Teva Takeda Yakuhin Ltd." in Japan
2016-03-29Takeda and Lundbeck Receive Complete Response Letter for Brintellix® (vortioxetine) sNDA
2016-03-19New Data Presented at European Crohn's and Colitis Organisation (ECCO) Scientific Meeting on Efficacy of Long-Term Vedol...
2016-03-15Takeda and Frazier Healthcare Partners Launch Outpost Medicine to Develop New Therapeutics in Urology and Gynecology
2016-03-15Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in United States
2016-02-26Japanese MHLW Grants Orphan Drug Designation in Japan to Takeda's Oral Proteasome Inhibitor Ixazomib for Patients with R...
2016-02-26Takeda Obtains New Drug Application Approval for Helicobacter pylori[?]Eradication triple-drug Blister Packs Containing ...
2016-02-24Takeda's Annual Report 2015 and CSR Data Book 2015 Receives Good Performance Prize in the Environmental Report Section o...
2016-02-10Takeda and Zinfandel Pharmaceuticals Complete Enrollment in TOMMORROW Trial
2016-02-04FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Cer...
2016-02-03Takeda reports results for three quarters (April-December) of FY2015, Reaffirms management guidance for the full year
2016-02-03Takeda Intends to Establish a Wholly Owned SubsidiaryOperating in the Consumer Healthcare Business in Japan
2016-02-03Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-...
2016-02-03Takeda Intends to Establish a Wholly Owned Subsidiary Operating in the Consumer Healthcare Business in Japan
2016-01-22European Commission Approves Label Variation for ADCETRIS® (Brentuximab Vedotin) to Include Data on Retreatment of Adult...
2016-01-22Takeda Announces New Drug Application Approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hi...
2016-01-21Takeda Recognized as one of the Global 100 Most Sustainable Corporations
2016-01-12Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases
2016-01-08Takeda to Present at the 34th Annual J.P. Morgan Healthcare Conference
2016-01-08Takeda and NsGene Partner to Perform Research in Cell Encapsulation Therapies for Parkinson's Disease
2016-01-06Takeda Acquires U.S. Biologics Manufacturing Facility
2016-01-06Takeda and Enterome Enter Strategic Drug Discovery Collaboration Focused on Microbiome Targets Across Multiple Gastroint...
2015-12-28Takeda Provides Further Information about its New Business Venture with Teva
2015-12-28Takeda Announces Details of New Business Venture with Teva in Japan
2015-12-16Benefit/Risk Profile Remains Positive for Pioglitazone as an Important Treatment Option for Type 2 Diabetes
2015-12-16Takeda Announces Sale of Respiratory Portfolio to AstraZeneca
2015-12-15Kyoto University's Center for iPS Cell Research Application and Takeda Launch the Joint Program for iPS Cell Application...
2015-12-15Takeda's "Leuplin® PRO for Injection Kit 22.5 mg" Now Available for the Treatment of Prostate Cancer/Premenopausal Breas...
2015-12-12NINLARO® (ixazomib) Now Available for Patients
2015-12-08Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases
2015-12-07Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteaso...
2015-12-07Takeda Reports Five-Year Overall Survival Data For ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Rel...
2015-11-30Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs of Patients and Growing Importance of Generi...
2015-11-26"Copaxone® Subcutaneous Injection 20 mg Syringe" Now Available for the Treatment for Multiple Sclerosis in Japan
2015-11-21U.S. FDA Approves Takeda's NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma
2015-11-13Takeda Obtains "Platinum Kurumin" Certification For Creating a Supportive Workplace for Employees with Children
2015-11-06Takeda to Present Data from Ixazomib's Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Societ...
2015-10-30Takeda reports results for the first half of FY2015 Confirms management guidance for the full year
2015-10-28Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuxi...
2015-10-20Takeda Presents Vedolizumab Data at the 2015 American College of Gastroenterology (ACG) Annual Meeting and United Europe...
2015-09-29Takeda selected for the sixth consecutive year for Dow Jones Sustainability Asia Pacific Index
2015-09-28New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of M...
2015-09-28Takeda Obtained New Drug Application Approval of "Leuplin® PRO for injection kit 22.5 mg" in Japan for the Treatment of ...
2015-09-28Takeda Submits a New Drug Application for the Fixed-Dose Combination of Nesina® and Metformin Hydrochloride for the Trea...
2015-09-24Takeda to Highlight Ixazomib Clinical Development Programat Upcoming International Myeloma Workshop
2015-09-14Takeda joins WIPO Re:Search to Accelerate R&D of New Drugs For Neglected Tropical Diseases, Malaria and TB
2015-09-12More than 96 Percent of Claimants Opt-In to ACTOS Resolution Program;Takeda Expects Resolution to Become Effective Once ...
2015-09-11Gencia and Takeda Team to Discover and Develop Novel Class of Mitochondrial Therapeutics
2015-09-09U.S. FDA Grants Priority Review to Takeda's Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
2015-08-27Takeda and Nanotherapeutics Announce Agreement to Expand Takeda's Commercialization and Technology Access Rights in Supp...
2015-08-21Takeda Announces European Medicines Agency Acceptance of Ixazomib's Marketing Authorization Application for Patients wit...
2015-08-11FDA Accepts a Supplemental New Drug Application for Review of Brintellix® (vortioxetine) Clinical Trial Data That Assess...
2015-07-31Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA ...
2015-07-31Takeda Publishes Annual Report 2015
2015-07-30Takeda reports 1st quarter results of FY2015 with underlying revenue growth of +6.1%
2015-07-28Takeda Included in the FTSE4Good Global Index for the 11th Consecutive Year
2015-07-27European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myelo...
2015-07-27DNDi and Takeda Collaborate for the Lead Optimization for Aminopyrazole Series for Visceral Leishmaniasis
2015-07-15Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
2015-06-26Takeda Announces New Assignment of Directors
2015-06-24Takeda Announces CFO François-Xavier Roger to Join Nestlé S.A.
2015-06-12Takeda's Statement on the Order Issued by the Japanese Ministry of Health Labour and Welfare regarding the Pharmaceutica...
2015-06-08Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes ...
2015-06-03Takeda Announces Consolidation of U.S. Vaccine Sites in Boston/Cambridge Area
2015-05-29Civil Society Initiative Subsidy Program Takeda Well-Being Program: Giving Children in Long-term Treatment the Energy to...
2015-05-28ZAFATEK® Now Available for the Treatment of Type 2 Diabetes in Japan
2015-05-19Takeda Announces Seasonal Influenza Vaccine Sales Agreement with Kaketsuken in Japan
2015-05-19Continuation and Partial Revision of Long-Term Incentive Plan for Members of the Board of Directors in Fiscal 2015
2015-05-19Continuation and Partial Revision of Long-Term Incentive Plan (Global Long-Term Incentive Plan) for Company Group Manage...
2015-05-15Takeda reports top line results in line with guidance, with underlying growth of +2.8% EPS affected by one-time charges ...
2015-05-13Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma
2015-05-12Takeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as Maintenance Therapy for Newly Diagnosed M...
2015-05-08National Cancer Center of Japan and Takeda Partner to Discover Anti-Cancer Agents
2015-05-07Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate their Agreem...
2015-04-29Takeda Agrees to Settle ACTOS Product Liability Lawsuits and Claims; Takeda Stresses Continued Commitment to ACTOS
2015-04-29Notice of the Latest Estimate of Consolidated Financials for FY2014 (IFRS) and Discrepancy from the Previous Forecast
2015-04-20Takeda Announces Research Collaboration with Keio University School of Medicine and Niigata University
2015-04-17CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research
2015-04-15FDA Advisory Committee Reviews Takeda's Alogliptin EXAMINE Cardiovascular Safety Outcomes Trial
2015-04-01Transfer of Shares of Mizusawa Industrial Chemicals, Ltd.
2015-03-26New Drug Application Approval of Zafatek® Tablets for the treatment of Type 2 Diabetes in Japan
2015-03-26New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan
2015-03-24Takeda Licenses Rights to Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology
2015-03-10Takeda Announces Publication in The Lancet of a Post Hoc Analysis of Data from the EXAMINE Cardiovascular Safety Outcome...
2015-03-10Takeda Hosts Investor Briefing on its Global Leadership in Gastroenterology
2015-03-10Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
2015-03-09Completion of donations to Takeda's "Support for Japan's Vitality and Recovery" Program activities that support reconstr...
2015-03-04Takeda Announces Appointment of Christophe Weber as Chief Executive Officer
2015-02-26TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan
2015-02-25Takeda's Annual Report 2014 and CSR Data Book 2014 Receive the Environmental Communication Awards Good Performance Prize...
2015-02-25Takeda Regroups Singapore Operations in New, Expanded Office
2015-02-24Takeda to Acquire Select Portfolio from Neutec, Significantly Enhancing its Business in Turkey
2015-02-20Queen Mary University of London and Takeda Announce Research Collaboration To Develop Novel Therapies in Gastroenterolog...
2015-02-17Takeda Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) in Patients with Advanced Non-Squamous Non-Small C...
2015-02-10Takeda Announces Appointment of New Senior Leadership
2015-02-10Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refr...
2015-02-06Construction Started on Shin-Tokyo Takeda Bldg. (provisional name)
2015-02-02Takeda Announces Discontinuation of Phase 2 Program for DTaP/sIPV Vaccine in Japan
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.